ConductScience.org, home

Paper32246720

SynergyFinder 2.0: visual analytics of multi-drug combination synergies.

Ianevski A and 2 others. Nucleic Acids Res, 2020. Cited by 692 papers, by iCite.

Cite this record

ConductScience Library. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Papers, record 32246720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32246720

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
SynergyFinder 2.0: visual analytics of multi-drug combination synergies.
PubMed
Journal
Nucleic Acids Res
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
692
iCite
Relative citation ratio, by iCite
28.5
iCite
Revised in PubMed
2024-07-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ianevski AAleksandr
2Giri AKAnil K
3Aittokallio TTero

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug SynergismMajor topic
Drug Therapy, CombinationMajor topic
SoftwareMajor topic
Computer Graphics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in35713562Correction to 'SynergyFinder 2.0: visual analytics of multi-drug combination synergies'.https://conductscience.org/library/papers/35713562

Source PubMed

Download CSV of comments and corrections

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132012154SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.PLoS Comput Biol2020https://conductscience.org/library/papers/32012154PubMed
229026882Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis.Sci Adv2017https://conductscience.org/library/papers/29026882PubMed
329483097Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.Cancer Res2018https://conductscience.org/library/papers/29483097PubMed
426355399A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma.Sultan Qaboos Univ Med J2015https://conductscience.org/library/papers/26355399PubMed
531287813Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.PLoS Med2019https://conductscience.org/library/papers/31287813PubMed
631734160Emergent Gene Expression Responses to Drug Combinations Predict Higher-Order Drug Interactions.Cell Syst2019https://conductscience.org/library/papers/31734160PubMed
726171228Analysis of drug combinations: current methodological landscape.Pharmacol Res Perspect2015https://conductscience.org/library/papers/26171228PubMed
825157754Computational tools for fitting the Hill equation to dose-response curves.J Pharmacol Toxicol Methods2015https://conductscience.org/library/papers/25157754PubMed
930596642Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment.PLoS Comput Biol2018https://conductscience.org/library/papers/30596642PubMed
1031518641Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.Drug Discov Today2019https://conductscience.org/library/papers/31518641PubMed
1130392419Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults.Expert Rev Anti Infect Ther2018https://conductscience.org/library/papers/30392419PubMed
1212829555Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.BMJ2003https://conductscience.org/library/papers/12829555PubMed
1328338065Prospects for combining targeted and conventional cancer therapy with immunotherapy.Nat Rev Cancer2017https://conductscience.org/library/papers/28338065PubMed
1430777010Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.BMC Bioinformatics2019https://conductscience.org/library/papers/30777010PubMed
1524613352Uncovering scaling laws to infer multidrug response of resistant microbes and cancer cells.Cell Rep2014https://conductscience.org/library/papers/24613352PubMed
1628446463The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.Cancer Res2017https://conductscience.org/library/papers/28446463PubMed
1728379339SynergyFinder: a web application for analyzing drug combination dose-response matrix data.Bioinformatics2017https://conductscience.org/library/papers/28379339PubMed
1827562164Prediction of multidimensional drug dose responses based on measurements of drug pairs.Proc Natl Acad Sci U S A2016https://conductscience.org/library/papers/27562164PubMed
1931575655Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.Mol Cancer Ther2020https://conductscience.org/library/papers/31575655PubMed
2031594982Nonlinear mixed-effects models for modeling in vitro drug response data to determine problematic cancer cell lines.Sci Rep2019https://conductscience.org/library/papers/31594982PubMed

See all 35 referencesDownload CSV of references

Cited by534

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 692 citations.

PMIDTitleJournalYearIn PapersSource
42948370Identification of FDA-approved IMPDH inhibitors boosting the broad-spectrum antiviral potential of ribavirin through depleting cellular GTP pool.Acta Pharm Sin B2026https://conductscience.org/library/papers/42948370PubMed
42919347ComplexMatrixComb: predicting anticancer drug combination dosages for target growth inhibition via complex-number matrix factorization.J Cheminform2026https://conductscience.org/library/papers/42919347PubMed
42889628Berberine and Etoposide Exert Synergistic Anticancer Effects in A431 Epidermoid Carcinoma Cells.ACS Omega2026https://conductscience.org/library/papers/42889628PubMed
42875447Multi-omics profiling identifies triciribine as a biomarker-guided antimetabolite therapy for acute lymphoblastic leukemia.NPJ Precis Oncol2026https://conductscience.org/library/papers/42875447PubMed
42815467EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer.Cell Rep Med2026https://conductscience.org/library/papers/42815467PubMed
42797238Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics2026https://conductscience.org/library/papers/42797238PubMed
42796579GC-MS Profiling, Antioxidant and Enzyme Inhibitory Activities of Basil (Ocimum basilicum L.) and Clove (Syzygium aromaticum L.) Essential Oils and Their Binary Mixtures.Molecules2026https://conductscience.org/library/papers/42796579PubMed
42660974Cheminformatic identification of small molecules targeting acute myeloid leukemia.Leukemia2026https://conductscience.org/library/papers/42660974PubMed
42656441Eupatilin-derived compounds enhance antitumor activity and doxorubicin efficacy in triple-negative breast cancer.Front Oncol2026https://conductscience.org/library/papers/42656441PubMed
42625328CDK12/13 Inhibition Induces DNA Hypomethylation and Sensitizes Cancer Cells to Compounds Targeting DNA-PK.J Cell Mol Med2026https://conductscience.org/library/papers/42625328PubMed
42618565Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42618565PubMed
42605598Lignin Mimicking Protein Methylation Augments the Efficacy of FOLFOX Chemotherapy by Anchoring Thymidylate Synthase.Adv Mater2026https://conductscience.org/library/papers/42605598PubMed
42550688The conserved bridging domain on HCV E1E2 glycoprotein complex is targeted by neutralizing antibodies from diverse lineages.Cell Rep2026https://conductscience.org/library/papers/42550688PubMed
42515757Angelica sinensis as a Multi-Targeted Natural Product Candidate: Constituent-Specific Mechanisms, Exposure Constraints, and Translational Development Challenges.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42515757PubMed
42493737Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery.Chem Biol Drug Des2026https://conductscience.org/library/papers/42493737PubMed
42493544Activation of the NF-κB/ALDH1A1 signaling promotes non-mutational resistance to EGFR-TKIs in non-small cell lung cancer.Oncogene2026https://conductscience.org/library/papers/42493544PubMed
42484926Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin.Med Oncol2026https://conductscience.org/library/papers/42484926PubMed
42448681Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.Nat Commun2026https://conductscience.org/library/papers/42448681PubMed
42303049Drug combination treatment as a strategy for inhibiting human adenovirus replication.Antiviral Res2026https://conductscience.org/library/papers/42303049PubMed
42294111From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models.Blood Neoplasia2026https://conductscience.org/library/papers/42294111PubMed

See all 534 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32246720

GET https://conductscience.org/api/papers/v1/32246720/references?page=2